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OBJECTIVE—In obesity, an increased macrophage inﬁltration
in adipose tissue occurs, contributing to low-grade inﬂammation
and insulin resistance. Epidermal growth factor receptor (EGFR)
mediates both chemotaxis and proliferation in monocytes and
macrophages. However, the role of EGFR inhibitors in this
subclinical inﬂammation has not yet been investigated. We
investigated, herein, in vivo efﬁcacy and associated molecular
mechanisms by which PD153035, an EGFR tyrosine kinase
inhibitor, improved diabetes control and insulin action.
RESEARCH DESIGN AND METHODS—The effect of
PD153035 was investigated on insulin sensitivity, insulin signal-
ing, and c-Jun NH2-terminal kinase (JNK) and nuclear factor
(NF)-B activity in tissues of high-fat diet (HFD)-fed mice and
also on inﬁltration and the activation state of adipose tissue
macrophages (ATMs) in these mice.
RESULTS—PD153035 treatment for 1 day decreased the protein
expression of inducible nitric oxide synthase, tumor necrosis
factor (TNF)-, and interleukin (IL)-6 in the stroma vascular
fraction, suggesting that this drug reduces the M1 proinﬂamma-
tory state in ATMs, as an initial effect, in turn reducing the
circulating levels of TNF- and IL-6, and initiating an improve-
ment in insulin signaling and sensitivity. After 14 days of drug
administration, there was a marked improvement in glucose
tolerance; a reduction in insulin resistance; a reduction in
macrophage inﬁltration in adipose tissue and in TNF-, IL-6, and
free fatty acids; accompanied by an improvement in insulin
signaling in liver, muscle, and adipose tissue; and also a decrease
in insulin receptor substrate-1 Ser
307 phosphorylation in JNK and
inhibitor of NF-B kinase (IKK) activation in these tissues.
CONCLUSIONS—Treatment with PD153035 improves glucose
tolerance, insulin sensitivity, and signaling and reduces subclin-
ical inﬂammation in HFD-fed mice. Diabetes 58:2910–2919,
2009
E
pidermal growth factor receptor (EGFR) ty-
rosine kinase inhibitors are used in the clinic to
treat malignancies (1). It has recently been
observed that a modest number of patients,
suffering from both malignancies and type 2 diabetes, were
successfully treated not only for their malignancies but
also for diabetes when given some tyrosine kinase inhibi-
tors (2–5). However, the molecular mechanisms that ac-
count for the effect of these drugs on insulin action and
glucose metabolism are unknown.
Insulin stimulates a signaling network composed of a
number of molecules, initiating the activation of insulin
receptor tyrosine kinase and phosphorylation of insulin
receptor substrates, including insulin receptor substrate
(IRS)-1 and IRS-2 (6–8). Following tyrosine phosphoryla-
tion, IRS-1/IRS-2 bind and activate the enzyme phosphati-
dylinositol 3-kinase (PI3-K). The activation of PI3-K
increases serine phosphorylation of Akt, which is respon-
sible for most of the metabolic actions of insulin, such as
glucose transport, lipogenesis, and glycogen synthesis
(7,8).
In the most prevalent forms of insulin resistance, diet-
induced obesity, and type 2 diabetes, there is a downregu-
lation in this signaling pathway in insulin-sensitive tissues,
parallel to a state of chronic low-grade inﬂammation (6).
Several serine/threonine kinases are activated by inﬂam-
matory or stressful stimuli and contribute to inhibition of
insulin signaling, including c-Jun NH2-terminal kinase
(JNK) (9–13) and inhibitor of nuclear factor (NF)-B
kinase (IKK) (12,14). In obesity, an increased macro-
phage inﬁltration in adipose tissue occurs, contributing to
this low-grade inﬂammation (15–17), which has an impor-
tant role in the increased tissue production of proinﬂam-
matory molecules and acute-phase proteins associated
with obesity (13,14). EGFR has been described in mono-
cytes and in macrophages and mediates both chemotaxis
and proliferation in macrophages (18–20). However, the
role of EGFR inhibitors on this subclinical inﬂammation of
obesity was not yet investigated.
PD153035 has been shown to possess highly potent and
selectively inhibitory activity against EGFR tyrosine ki-
nase and rapidly suppresses autophosphorylation of EGFR
at low nanomolar concentrations in ﬁbroblasts and human
epidermoid carcinoma cells, as well as selectively block-
ing EGF-mediated cellular processes, including mitogene-
sis and early gene expression (21–23). In addition,
PD153035 has been shown to reduce JNK and IKK/IB/
NF-B pathways (24,25). Moreover, EGFR and other ty-
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the growth of monocyte/macrophages, suggesting possible
mechanisms to improve insulin action (26–29).
Herein, we investigated the in vivo efﬁcacy and associ-
ated molecular mechanisms by which PD153035, an EGFR
tyrosine kinase inhibitor, improved diabetes control and
insulin action. We studied the effect of acute (1 day) or
chronic (14 days) administration of PD153035 on insulin
sensitivity, insulin signaling, and JNK and NF-B activity in
liver, muscle, and adipose tissue of high-fat diet (HFD)-fed
mice and also on the inﬁltration and activation state of
adipose tissue macrophages (ATMs) in these mice.
RESEARCH DESIGN AND METHODS
Male Swiss mice were obtained from the University of Campinas, Sa ˜o Paulo.
The mice were bred under speciﬁc pathogen-free conditions at the Central
Breeding Center of the University of Campinas. Antiphosphotyrosine (-PY),
anti-IR (-IR), anti–IRS-1, anti-Akt1/2, anti–p-JNK, anti–inducible nitric oxide
synthase (iNOS), anti–tumor necrosis factor (TNF)-, anti–interleukin
(IL)-6, anti-EGFR, anti-caveolin, anti-actin, anti-IKK, anti-pIKK, anti–p-
c-Jun, and anti-IB antibodies were from Santa Cruz Technology (Santa
Cruz, CA). Anti-pAkt was from Cell Signaling Technology (Beverly, MA).
Anti–phospho-IRS-1
ser307 was obtained from Upstate Biotechnology (Lake
Placid, NY). Human recombinant insulin was from Eli Lilly and Company
(Indianapolis, IN). Routine reagents were purchased from Sigma Chemical
(St. Louis, MO), unless speciﬁed elsewhere.
Compound PD153035 [4-N-(3-bromo-phenyl)amino-6,7-dimethoxyquinazo-
line hydrochloride] was synthesized, as previously described (30). The com-
pound was 99% pure, as determined by elemental analysis, high-
performance liquid chromatography, mass spectrometry, and
1H and
13C
nuclear magnetic resonance (30).
Animal care and experimental procedures. All experiments were ap-
proved by the ethics committee of the State University of Campinas. Eight-
week-old male Swiss mice were divided into four groups with similar body
weights and assigned to receive the following diet and/or treatment: control
group received a standard rodent diet and water ad libitum; HFD group
received an HFD consisting of 55% calories from fat, 29% from carbohydrate,
and 16% from protein for 8 weeks; and HFD with PD153035 for 14 days
(HFPD14days) received the same HFD for 8 weeks, but in the last 2 weeks
these animals also received PD153035 (30 mg/kg) by gavage once a day. A
group of HFD animals also received the same dose of PD153035 at 24 and 2 h
before the experiments, and this group was called HFPD1day. Body weight
and food intake were measured weekly. Glucose tolerance tests and insulin
tolerance tests were performed on these mice after 8 weeks on the diets, as
previously described (31,32).
Assays. Insulin, leptin, and adiponectin concentrations were determined by
enzyme-linked immunosorbent assay (ELISA) (Linco). Serum free fatty acid
(FFA) levels were analyzed using the NEFA-kit-U (Wako Chemical, Neuss,
Germany), with oleic acid as a standard. Glucose values were measured from
whole venous blood with a glucose monitor (Glucometer; Bayer). Serum
concentrations of IL-6 and TNF- were determined using mouse IL-6 ELISA
and mouse TNF- ELISA (Pierce Endogen, Rockford, IL). Monocyte chemoat-
tractant protein (MCP)-1, MCP-2, and MCP-3 ELISA kits were purchased from
Antigenix America (Huntington Station, NY).
Light microscopy and morphometry. Mice were fasted for 12 h and killed
with an overdose of anesthetic (sodium thiopental). Epididymal, retroperito-
neal, and mesenteric adipose tissues were dissected and assessed by light
microscopy and morphometry. Tissue sections were observed with a Zeiss
Axiophot light microscope using a 40 objective, and digital images were
captured with a Canon PowerShot G5. Crown-like structure (CLS) density
(average CLS within 10 high-power ﬁelds, per animal) and mean adipocyte
surface area (average surface area of 30 randomly sorted adipocytes, per
animal) were determined using the Imagelab Analysis software (version 2.4),
as previously described (33).
Tissue extraction, immunoprecipitation, and immunoblotting. Mice
were anesthetized by intraperitoneal injection of sodium thiopental and were
used 10–15 min later (i.e., as soon as anesthesia was assured by the loss of
pedal and corneal reﬂexes). Five minutes after the insulin injection (3.8
units/kg i.p.) liver, muscle, and adipose tissue were removed, minced coarsely,
and homogenized immediately in extraction buffer, as described elsewhere
(34). Extracts were used for immunoprecipitation with -IR, -IRS-1, -EGFR,
and protein A-sepharose 6MB (Pharmacia, Uppsala, Sweden). The precipi-
tated proteins and/or whole tissue extracts were subjected to SDS-PAGE and
immunoblotting as previously described (6,31).
Determination of NFB activation. NFB p50 activation was determined in
nuclear extracts from liver, muscle, and adipose tissue by ELISA (89858;
Pierce Biotechnology), according to the recommendations of the
manufacturer.
Isolation of the stroma vascular fraction and adipocyte fraction of
adipose tissue. Epididymal, retroperitoneal, or mesenteric fat pads were
excised, and isolation of the stroma vascular fraction and adipocyte fraction
of adipose tissue were performed, as previously described (33). A summary of
the method is presented in the online appendix (available at http://diabetes.
diabetesjournals.org/cgi/content/full/db08-0506/DC1).
Arginase assay. Arginase activity assays were performed, as previously
described (35). A summary of the method is presented in the online appendix.
Statistical analysis. Data are expressed as means  SE, and the number of
independent experiments is indicated. For statistical analysis, the groups were
compared using a two-way ANOVA with the Bonferroni test for post hoc
comparisons. The level of signiﬁcance adopted was P  0.05.
RESULTS
Effect of PD153035 on EGFR tyrosine phosphoryla-
tion in liver, muscle, and adipose tissue of mice. The
drug PD153035 was developed in 1994 as a speciﬁc ty-
rosine kinase inhibitor of the EGFR (20). To investigate
the effect of PD153035 administration on EGFR phosphor-
ylation, we immunoprecipitated liver, muscle, and adipose
tissue extracts of controls, HFD-fed animals, and HFD-fed
animals treated with PD153035 for 1 or 14 days with
anti-EGFR antibody and performed immunoblotting with
anti-phosphotyrosine antibody. The results showed that
PD153035 administration was able to reduce EGFR ty-
rosine phosphorylation in the three tissues by 70–90% in a
similar fashion after 1 or 14 days (Fig. 1A–C). HFD did not
change the tissue levels of EGFR in liver, muscle, and
epidydimal fat pad; however, there was an increase in
EGFR expression (Fig. 1C) and in tyrosine phosphoryla-
tion in the mesenteric and retroperitoneal fat pads. The
reduction in EGFR tyrosine phosphorylation, induced by
PD153035, was greater in the mesenteric and retroperito-
neal fat pads compared with the epididymal fat pad (Fig.
1C). PD153035 treatment reduced EGFR tyrosine phos-
phorylation in a dose-dependent manner in liver, muscle,
and retroperitoneal tissues (online appendix Fig. S1).
Effect of PD153035 on body weight and fat pads in
HFD-fed mice. Eight-week-old male Swiss mice were
placed on HFD and then supplemented, or not, with
PD153035 on the last day (HFPD1) or during 14 days
(HFPD14) before the experiments. Weight gain after 8
weeks was similar in HFD or HFPD groups and was higher
in these groups than in the control group that received
standard rodent diet (Fig. 1D). There is a slight reduction
in body weight after 14 days of PD153035 compared with
HFD or HFDPD1, which is not statistically signiﬁcant.
Daily food intake was similar in HFD or HFPD, and 8-week
cumulative food intake was higher for both groups on HFD
(data not shown). As expected, the epididymal, retroperi-
toneal, and mesenteric fat pad weights were higher in the
HFD group, and PD153035 treatment for 1 day did not
change these fat pad weights, but after 14 days there was
a signiﬁcant reduction in retroperitoneal and mesenteric
fat pad weights (Fig. 1E–G).
Effect of PD153035 on metabolic parameters in HFD-
fed mice. The fasting plasma glucose levels were higher in
HFD and in HFPD1 than in the other groups (Figs. 1H).
PD153035 treatment reduced fasting plasma glucose levels
in a dose-dependent manner (Fig. S2). During the glucose
tolerance test, the plasma glucose and serum insulin levels
were signiﬁcantly higher in HFD and HFPD1 mice com-
pared with controls, and PD153035 administration for 14
days improved glucose tolerance and reduced insulin
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disappearance rate was lower in HFD and in HFPD1
groups, and PD153035 administration for 14 days
(HFPD14) reversed these alterations (Fig. 1K). Taken
together, the lower insulin levels during the glucose toler-
ance test and the increase in glucose disappearance rate
during the insulin tolerance test after PD153035 treat-
ment for 14 days suggest that this drug improves insulin
sensitivity. FFA levels were signiﬁcantly higher in HFD
and HFPD1 and returned to levels close to those of the
control group after 14 days of PD153035 administration
(Fig. 1L).
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FIG. 1. Effects of acute or chronic PD153035 administration in fed mice. (A–C, upper panels). Representative blots show the tyrosine
phosphorylation of EGFR of control mice, HFD mice, and HFDPD 1 and 14 days in liver (A), muscle (B), and adipose (C). Total protein expression
of EGFR (A–C, lower panels). D: Body weight. E: Epididymal fat pad weight. F: Retroperitoneal fat pad weight. G: Mesenteric fat pad weight. H:
Fasting plasma glucose. I: Glucose tolerance test. J: Serum insulin during glucose tolerance test. K: Glucose disappearance rate. L: Serum FFAs.
Data are presented as means  S.E.M from six to eight mice per group. *P < 0.05 vs. control group; #P < 0.01 vs. HFD. IB, immunoblot; IP,
immunoprecipitate.
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2912 DIABETES, VOL. 58, DECEMBER 2009 diabetes.diabetesjournals.orgEffect of PD153035 on insulin signaling in liver,
muscle, and retroperitoneal adipose tissue of HFD-
fed mice. In liver, muscle, and retroperitoneal adipose
tissues, insulin-induced IR (Fig. 2A–C) and IRS-1 tyrosine
phosphorylation (Fig. 2D–F) and Akt serine phosphoryla-
tion (Fig. 2G–I) were reduced by 50–70% in mice fed on an
HFD compared with controls. The treatment with
PD153035 for 1 day did not change the insulin-induced
tyrosine phosphorylation levels of IR and IRS-1 (data not
shown) and also did not improve Akt serine phosphoryla-
tion levels in liver muscle and adipose tissues (Fig. 2G–I
and online appendix Fig. S3). However, 14 days of treat-
ment reversed these reductions in the three tissues studied
(Fig. 2A–I). The protein concentration of IR, IRS-1, and
Akt in liver, muscle, and retroperitoneal adipose did not
change between the groups.
The effect of PD153035 improving Akt phosphorylation
in HFD-fed mice was dose dependent (online appendix
Fig. S3). In control animals, PD153035 did not change
insulin-induced Akt phosphorylation in liver, muscle, or
epididymal adipose tissue or glucose uptake in isolated
muscle (online appendix Fig. S4).
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FIG. 2. Effects of PD153035 administration on insulin signaling in fed mice. Representative blots show tyrosine phosphorylation of IR in
liver (A), muscle (B), and adipose (C) of control mice, HFD mice, and HFDPD during 14 days (upper panels). Total protein expression of
IR (A–C, lower panels). Tyrosine phosphorylation of IRS-1 in liver (D), muscle (E), and retroperitoneal (F) of control mice, HFD mice,
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days vs. HFD. IB, immunoblot.
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307 phosphorylation of IRS-1 and activation of
JNK and IKK in liver, muscle, and retroperitoneal
tissue of HFD-fed mice treated with PD153035. IKK
activity was monitored using IKK phosphorylation and
IB protein abundance, as previously described (12).
IKK phosphorylation was increased and IB protein
levels were reduced in liver, muscle, and retroperitoneal
adipose tissue of mice fed an HFD or HFPD1 diet but not
in these tissues of HFPD14 mice (Fig. 3A–F). We also
measured the nuclear NF-B subunit p50 activation and
found an increase in the DNA binding of nuclear p50 in
liver, muscle, and retroperitoneal of mice on an HFD and
HFPD1, but there was a clear decrease in the three tissues
in HFPD14 (Fig. 3G–I). JNK activation was determined by
monitoring phosphorylation of JNK (Thr183 and Tyr185)
and the protein levels of p-c-Jun. JNK phosphorylation and
p-c-Jun were increased in liver, muscle, and white adipose
tissue (WAT) of mice fed on an HFD and HFPD1, and this
increase was reversed by 14 days of PD153035 treatment
(Fig. 3J–O). We tested Ser
307 phosphorylation of IRS-1 in
liver, muscle, and WAT in the four groups of mice. Ser
307
phosphorylation was induced by an HFD in the three
tissues of mice, and the treatment with PD153035 for 14
days reversed this alteration (Fig. 3P–R).
Effect of PD153035 on retroperitoneal adipose tissue
morphology and ultrastructural features in HFD-fed
mice. Morphometric analysis revealed that in retroperito-
neal fat pad, adipocytes from HFPD14 were consistently
smaller than adipocytes from control mice fed on an HFD
or HFPD1, with an average 40% decrease in size (Fig. 4A
and B). In mesenteric and epididymal depots, the reduc-
tion in adipocytes in HFPD14 was 30–40% average de-
crease in size (online appendix Fig. S5). In addition, the
frequency and distribution of mature macrophages in ﬁxed
WAT differed between the groups. As previously described
(15), macrophages were aggregated in CLSs, which con-
tained up to 15 macrophages surrounding what appeared
to be individual adipocytes. CLS formation was a rare
event in control mice (24  9) but was increased 200-
fold (489  58) in control mice on HFD or on HFPD1
(506  66) and only 	8-fold (150  23) in HFPD14,
indicating a much lower macrophage inﬁltration in the
WAT of the latter group. To analyze if PD153035 was able
to reduce macrophage inﬁltration in retroperitoneal adi-
pose tissue, immunohistochemical staining using speciﬁc
macrophage marker F4/80
 was performed. As shown in
Fig. 4C and D, HFD increased F4/80
 staining, and
PD153035 treatment for 14 days reduced this staining,
suggesting less macrophage were present (Fig. 4C and D).
In epididymal and mesenteric fat pads (online appendix
Figs. S5 and S6) the results were very similar to the
retroperitoneal. As shown in Fig. 4E, treatment with
PD153035 signiﬁcantly impaired the migration of human
monocytic leukemia cell line (THP1) in a dose-response
manner (online appendix).
Effect of PD153035 on tissue protein levels of TNF-,
IL-6, and iNOS and arginase activity in adipocytes
and stroma vascular fraction. In retroperitoneal adi-
pose tissue, separation of the stroma vascular fraction
(SVF) from adipocytes of lean, HFD, HFPD1, and HFPD14
animals indicated that there was a modest increase in
TNF- protein expression in adipocytes from HFD animals
compared with controls and that PD153035 reduced the
expression of this cytokine only after 14 days of treatment
(Fig. 5A). In adipocytes, the expressions of IL-6 and iNOS
were higher in mice that received the HFD; these expres-
sions were not signiﬁcantly affected by PD153035 treat-
ment for 1day. However, after 14 days of PD153035
administration, there was a clear decrease in the expres-
sion of these proteins in adipose tissue (Fig. 5B and C).
Similar results were observed in liver and muscle (online
appendix Fig. S7). Treatment with PD153035 for 1 or 14
days reduced EGFR tyrosine phosphorylation in adipoc-
tyes (Fig. 5D) In SVF, the expressions of TNF-, IL-6, and
iNOS were also higher in HFD animals compared with
controls. Different from adipocytes, PD153035 administra-
tion for just 1 day was able to reduce the SVF expressions
of TNF-, IL-6, and iNOS, which were normalized after 14
days administration of this drug (Fig. 5F–H). There was a
signiﬁcant increase in EGFR tyrosine phosphorylation in
SVF of HFD group, and the treatment with PD153035 for 1
or 14 days induced a marked reduction in EGFR tyrosine
phosphorylation levels in SVF (Fig. 5I). Similar results
were observed in adipocytes and SVF from epididymal
(online appendix Fig. S8) and mesenteric (data not shown)
fat depots.
An important characteristic of the alternative macro-
phage activation state is the increased arginase activity
(35). Arginase activity was measured in adipocytes and
SVF samples from controls, HFD, and HFD rats treated
with PD153035 for 1 or 14 days. Results showed that the
activity of this enzyme did not differ between the isolated
adipocytes from the four groups of animals (Fig. 5K).
However, arginase activity was signiﬁcantly reduced in the
SVF of rats on an HFD, and a signiﬁcant increase was
observed after just 1 day of PD153035 administration.
After 14 days of treatment, arginase activity was similar to
that of control animals (Fig. 5K).
Adiponectin levels were reduced in control mice on an
HFD and HFPD1 but increased signiﬁcantly after 14 days
of PD153035 administration. (Fig. 5L). Serum leptin levels
were higher in the HFD group, and PD153035 administra-
tion did not change these levels (Fig. 5N). Serum TNF-
and IL-6 levels were higher in mice on an HFD; interest-
ingly, PD153035 administration for 1 day reduced the
levels of these cytokines. After 2 weeks of PD153035
treatment, TNF- and IL-6 returned to normal levels (Fig.
5M and O).
The protein levels of MCP-1 and MCP-3 were signiﬁ-
cantly increased in adipose tissue of HFD mice, and
treatment with PD153035 for 14 days signiﬁcantly reduced
these chemokines. MCP-2 protein levels were not inﬂu-
enced by high fat as previously described (36) or
PD153035 (Fig. 5P–R).
DISCUSSION
Our results show that the use of PD153035 (EGFR tyrosine
kinase inhibitor) in HFD-fed mice for 14 days induced a
marked improvement in glucose tolerance; a reduction in
insulin resistance; a reduction in macrophage inﬁltration
in adipocytes and in low-grade inﬂammation, accompa-
nied by an improvement in insulin signaling in liver,
muscle, and adipose tissue; and also an increase in serum
adiponectin levels.
It is important to emphasize that administration of
PD153035 for 1 day did not change insulin sensitivity/
signaling or macrophage inﬁltration in adipose tissue but
reduced the circulating levels of IL-6 and TNF-, probably
as a consequence of reduced activation of macrophage, as
shown by a reduction in the expression of these cytokines
in the SVF. These data suggest that the ﬁrst effect observed
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FIG. 3. Effects of PD153035 administration on modulators of insulin signaling. Representative blots show the expression of IKK phosphorylation
in liver (A), muscle (B), and retroperitoneal (C) of control mice, HFD mice, and HFDPD 1 and 14 days (upper panels). Total protein expression
of IKK (A–C, lower panels). IB in liver (D), muscle (E), and adipose (F) of control mice, HFD mice, and HFDPD 1 and 14 days. NFB p50
activation was determined in nuclear extracts from liver (G), muscle (H), and adipose (I) tissue by ELISA. JNK phosphorylation in liver (J),
muscle (K), and adipose (L) of control mice, HFD mice, and HFDPD 1 and 14 days (upper panels). Total protein expression of JNK (J–L, lower
panels). c-Jun phosphorylation in liver (M), muscle (N), and adipose (O) of control mice, HFD mice, and HFDPD 1 and 14 days. IRS1 serine 307
phosphorylation in liver (P), muscle (Q), and adipose (R) of control mice, HFD mice, and HFPD 1 and 14 days (upper panels). Total protein
expression of IRS-1 (P–R, lower panels). Data are presented as means  SE from six mice per group, *P < 0.05 vs. control group and #P < 0.05
vs. HFD. IB, immunoblot.
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Macrophage activation has been deﬁned across two sepa-
rate polarization states, M1 and M2 (35,37,38). M1 or
“classically activated” macrophages are induced by proin-
ﬂammatory mediators, such as lipopolysaccharide and
interferon-, and have enhanced cytokine production (IL-6
and TNF-) and generate reactive oxygen species such as
NO via activation of iNOS. M2 or “alternatively activated”
macrophages have low proinﬂammatory cytokine expres-
sion and, instead, generate high levels of the anti-inﬂam-
matory cytokines IL-10 and IL-1 decoy receptor. In
addition, in these macrophages, arginase production (an
enzyme that blocks iNOS activity) is increased (39). In
summary, M2 macrophages are believed to participate
in the blockade of inﬂammatory responses and in the
promotion of tissue repair (37). Our data show that
PD153035 treatment for just 1 day reduced the expression
of IL-6, TNF-, and iNOS in the SVF and, in parallel,
induced an increase in arginase activity, suggesting that
PD153035 may lead to a shift in the activation state of
ATMs, reducing the M1 proinﬂammatory state that con-
tributes to insulin resistance. Since EGFR tyrosine phos-
phorylation was increased in the SVF of HFD mice, it is
possible that the primary action of PD153035 is on ATMs,
but a direct relation between EGFR and macrophage
activation deserves further investigation.
In mice treated with PD153035 for 14 days, the HFD
induced a less marked macrophage inﬁltration in adipose
tissue, accompanied by an attenuated increase in TNF-,
IL-6, and FFAs. This decrease in macrophage inﬁltration
may be a direct effect of EGFR tyrosine kinase inhibition.
In agreement, our data show that PD153035 reduces
monocyte migration. Recent studies (21–23) demonstrated
that EGFR and/or other tyrosine kinase inhibitors inhibit
the growth and/or activation of some nonmalignant hema-
topoietic cells, including monocyte/macrophages. Interest-
ingly, another study (40) has shown that a reduction in
macrophage inﬁltration and/or resident alternatively acti-
vated macrophages can decrease local inﬂammation in
WAT. In accordance with this, our data show that in the
adipose tissue of HFD-fed mice treated with PD153035 for
14 days, in parallel with a reduction in macrophage
inﬁltration, there were lower expressions of TNF-, IL-6,
and iNOS, indicating that this drug decreases local inﬂam-
mation in WAT of HFD mice. In addition, in HFD mice
treated with PD153035 for 14 days there was also a
decrease in MCP-1 and MCP-3 in adipose tissue, which
may have a role in the reduced macrophage inﬁltration.
These results lead us to suggest that this decrease in
inﬂammation in WAT may have an important role in the
effect of PD153035, improving insulin resistance and glu-
cose tolerance in HFD mice.
The improvement in insulin action induced after 14 days
of PD153035 administration was also demonstrated at the
tissue level in the insulin signaling pathway. The blunted
insulin-stimulated IR tyrosine phosphorylation and phos-
phorylation of Akt and the increase of IRS-1 Ser
307 in liver,
muscle, and WAT of HFD mice was prevented by treat-
ment with PD153035, providing a biochemical correlate
for the increase in in vivo insulin sensitivity. Ser
307 is
reported to be a phosphoacceptor of JNK and IKK
(10,41); as previously described (42–45), our results also
show that these kinases are activated in tissues of HFD
mice. Our data demonstrated that PD 153035 administra-
tion for 14 days prevents the activation of IKK and JNK in
liver, muscle, and WAT, which may be a consequence of
the reduction in inﬂammation in WAT and in the circulat-
ing levels of FFAs, TNF-, and IL-6. However, we cannot
exclude the possibility of a direct effect of PD153035 on
JNK and IKK/NFB pathways as previously described in
cell culture (24,25), although our data show that acute
administration of PD153035 did not have this effect.
It is unlikely that PD153035 improved insulin action by a
direct effect on glucose transport in muscle because the
administration of this drug to isolated muscle did not
increase insulin-induced glucose uptake. Another mecha-
nism that may have contributed to the effect of PD153035
on glucose homeostasis is the reversal of the decreased
adiponectin levels observed in HFD mice. It is possible
that the reduced inﬂammatory state in adipose tissue and
smaller adipocytes in HFPD14 may have allowed the
restoration or even an increase in adiponectin secretion.
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FIG. 4. Effects of PD153035 on adipocyte morphology and activation
and migration of macrophages in adipocyte tissue. A: Histological
sections of retroperitoneal fat pads from control, HFD, and HFDPD
after 1 or 14 days, 50-m scale bar for all pictures. B: Quantiﬁcation of
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average adipocyte was calculated. C: Representative immunohisto-
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FIG. 5. Effect of PD153035 on tissue protein levels of TNF-, IL-6, and iNOS and arginase activity in adipocytes and SVF from retroperitoneal
adipose tissue. Representative blots show the tissue levels of TNF-, IL-6, iNOS, EGRF tyrosine phosphorylation, EGRF, Caveolin, and Cd68
protein expression in adipocytes (A–D) and TNF-, IL-6, iNOS, EGRF tyrosine phosphorylation, EGRF, Cd68, and actin protein expression in the
SVF (F–J). K: Arginase activity of adipocytes and SVF from control mice, HFD mice, and HFDPD 1 and 14 days. Serum levels of adiponectin (L),
TNF- (M), leptin (N), and IL-6 (O) and MCP-1 (P), MCP-2 (Q), and MCP-3 (R) protein expression were obtained using ELISA assay. Data are
presented as means  SE of six to eight mice per group. *P < 0.05 vs. control group; #P < 0.05 vs. HFD group.
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important than the total amount of fat. The adverse
metabolic impact of visceral fat has been attributed to
distinct biological properties of adipocytes in this depot,
including variations in the metabolic activity of fat cells
and in the expression of cytokines, hormones, and
polypeptides (46,47). Our data showed that HFD increased
EGFR expression and basal tyrosine phosphorylation in
mesenteric and retroperitoneal (internal fat depot) but not
in epididymal fat pads, suggesting a role of this receptor in
the development of central obesity and/or its metabolic
consequences. Moreover, the more marked decrease in
EGFR tyrosine phosphorylation after PD153035 treatment
in the internal fat depots accompanied the signiﬁcant
reduction in the weight of these fat depots. It is possible
that the decrease in fat depots may contribute to the
improvement in glucose tolerance and insulin sensitivity in
animals treated with PD153035 for 14 days. In this regard,
the regulation of EGFR in macrophages and in mesenteric
and retroperitoneal fat pads in HFD suggests that this
receptor and/or signaling pathway may have a role in the
insulin resistance of obesity and diabetes and deserves
further exploration.
In summary, our results show that the use of PD153035
for just 1 day was able to reduce the protein expressions of
iNOS, TNF-, and IL-6 in SVF. We can thus suggest that
PD153035 inhibits EGFR tyrosine kinase activity in ATMs,
reducing the M1 proinﬂammatory state as an initial effect.
This reduces the circulating levels of TNF- and IL-6,
initiating an improvement in insulin signaling and sensitiv-
ity. After 14 days of the drug administration, there was a
marked improvement in glucose tolerance; a reduction in
insulin resistance; a reduction in macrophage inﬁltration
in adipocytes and in TNF-, IL-6, and FFAs; accompanied
by an improvement in insulin signaling in liver muscle and
adipose tissue. We, therefore, suggest that PD153035 pre-
sents an attractive opportunity for the treatment of insulin
resistance and type 2 diabetes.
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